U.S. Capital Markets Stock News

NYSE:USFD
NYSE:USFDConsumer Retailing

US Foods (USFD) Is Up 8.2% After Reaffirmed 2026 Guidance And $1.36 Billion Buybacks ‑ What's Changed

On August 6, 2026, US Foods Holding Corp. reported higher second-quarter and year-to-date sales and net income, reaffirmed its 2026 net sales growth guidance of 4% to 6%, and completed share repurchases totaling 16,612,155 shares for about US$1.36 billion across two buyback authorizations. The combination of improved earnings, ongoing confidence in full-year performance, and sizable buybacks shrinking the share count highlights management’s focus on both operational execution and capital...
NYSE:ARLO
NYSE:ARLOElectronic

Arlo Technologies (ARLO) Could Be 29% Undervalued As 2026 Guidance Rises

Why Arlo Technologies stock is in focus after updated 2026 guidance Arlo Technologies (ARLO) is back on investor radars after raising its full year 2026 revenue and earnings guidance, alongside detailed outlooks around third quarter expectations and recent second quarter results. The company now expects 2026 revenue between US$580 million and US$600 million and diluted EPS between US$0.11 and US$0.21. Management also issued third quarter revenue guidance of US$140 million to US$150 million,...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Why Astera Labs (ALAB) Is Up 7.4% After Surging Q2 Results And Upbeat Q3 Guidance

Astera Labs, Inc. reported past second-quarter 2026 results showing sales of US$392.4 million and net income of US$153.09 million, alongside six-month sales of US$700.76 million and net income of US$233.4 million, all substantially higher than a year earlier. Alongside these results, the company issued upbeat third-quarter 2026 guidance, projecting US$540 million to US$560 million in revenue and GAAP diluted EPS of US$0.87 to US$0.92, underscoring management’s confidence in its current AI...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

EyePoint (EYPT) Completes Phase 3 Enrollment Early, Is The Stock Still Cheap?

EyePoint (EYPT) has just hit a key clinical milestone that puts fresh attention on its stock. The company completed enrollment ahead of schedule in its global Phase 3 COMO and CAPRI trials for DURAVYU in diabetic macular edema. See our latest analysis for EyePoint. The DURAVYU update comes after a sharp 8.26% 1 day share price return and 13.39% 7 day share price return, although the share price is still down 20.54% year to date while the 1 year total shareholder return is 35.78%. This...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance

Arcutis Biotherapeutics (ARQT) is back on investor radars after second quarter 2026 results showed revenue of $129.86 million, net income of $15.01 million, and raised full year net product sales guidance. See our latest analysis for Arcutis Biotherapeutics. The latest results and raised full year guidance have come alongside a 19.07% 3 month share price return and a 71.23% 1 year total shareholder return. However, shorter term share price returns over the past month and year to date have...
NasdaqGS:STX
NasdaqGS:STXTech

Seagate (STX) Balances AI-Focused Expansion With Steady Dividends – A Durable Strategy or Overreach?

Seagate Technology Holdings recently reported fiscal fourth quarter 2026 sales of US$3,629 million and full-year sales of US$12.20 billion, alongside higher net income and earnings per share, affirmed a quarterly dividend of US$0.74 per share, issued fiscal first quarter 2027 revenue guidance of about US$4.10 billion, and earlier this month presented its technology roadmap at the Future of Memory and Storage 2026 conference in Santa Clara. Together, the stronger recent financial performance,...
NYSE:AVY
NYSE:AVYPackaging

Avery Dennison (AVY) Lifted Its Guidance, Is The Stock Still Cheap?

Why Avery Dennison Stock Is Back in Focus After Q2 Avery Dennison (AVY) is drawing fresh attention after reporting higher Q2 2026 sales and net income, lifting its full-year earnings guidance, continuing its share buyback program, and declaring a new cash dividend. See our latest analysis for Avery Dennison. Avery Dennison’s recent Q2 earnings beat, higher full year guidance, share buybacks and the new dividend have coincided with a 10.25% 1 month share price return and a 6.08% 1 year total...
NYSE:MP
NYSE:MPMetals and Mining

3 Rare Earth Stocks Backed By The Push For Secure US Supply

Oil price volatility linked to Middle East supply concerns is refocusing attention on energy security and the materials that make cleaner tech possible. Rare earth metal stocks sit right in this crosscurrent, as countries seek both reliable power and more efficient electrification. For investors, that creates a focused way to gain exposure. This article walks through three rare earth stocks from our screener that stand out right now. The three rare earth stocks highlighted below are just a...
NYSE:USPH
NYSE:USPHHealthcare

Rising Sales but Falling EPS and New Dividend Might Change The Case For Investing In U.S. Physical Therapy (USPH)

U.S. Physical Therapy, Inc. has reported past second-quarter 2026 results, with revenue rising to US$214.06 million while net income fell to US$9.90 million, alongside a declared quarterly dividend of US$0.46 per share payable in September 2026. While the company is generating higher sales over both the quarter and first half of 2026, the sharper drop in earnings per share versus a year earlier highlights growing cost or reimbursement pressures that could matter for investors focused on...
NasdaqGS:SMCI
NasdaqGS:SMCITech

Super Micro Computer (SMCI) Could Be 27% Overvalued On $60b Of New AI Orders

Super Micro Computer (SMCI) has drawn fresh attention after reporting more than US$60b in new AI focused orders in a single quarter, lifting its backlog to record levels while the stock trades near US$31. See our latest analysis for Super Micro Computer. Against this backdrop of record AI orders, Super Micro Computer’s recent share price moves tell a mixed story. The stock is up 5.96% on a 1 day basis and has a 30 day share price return of 9.96%. However, the 1 year total shareholder return...
NYSE:DOW
NYSE:DOWChemicals

Dow (DOW) Lands Mattress Testing Deal, Is The Stock Trading At A Discount?

Dow (DOW) is in focus after SweetNight selected the company and GoodBed to run independent mattress testing and consumer education, aiming to provide clearer performance data and build trust in mattress purchases. See our latest analysis for Dow. Dow's latest mattress testing partnership comes against a mixed share price backdrop, with the stock down 24.3% over the past 90 days, yet showing a 20.9% year to date share price return and a 45.5% 1 year total shareholder return. This points to...
NYSE:CR
NYSE:CRMachinery

What Crane (CR)'s Acquisition-Fueled Guidance Hike Means For Shareholders

In late July 2026, Crane Company reported second-quarter 2026 results showing sales rising to US$724.7 million and net income of US$95.9 million, alongside affirming a regular quarterly dividend of US$0.255 per share for payment on September 9, 2026. The company also raised its full-year 2026 sales growth guidance into the mid-20% range, highlighting acquisitions as a key driver of its expanded outlook. Now we’ll explore how Crane’s raised full-year sales guidance, driven by acquisitions,...
NasdaqGS:TRIP
NasdaqGS:TRIPInteractive Media and Services

Tripadvisor (TRIP) Is Down 23.9% After Weaker Q2 Results And Planned TheFork Sale - What's Changed

In early August 2026, Tripadvisor, Inc. reported past second-quarter 2026 results showing sales of US$441.9 million and net income of US$22.4 million, both lower than a year earlier, alongside weaker earnings per share and a first-half net loss. Management also outlined plans to sell TheFork for US$700 million and highlighted how AI-driven shifts in travel search and competition are prompting a reassessment of Tripadvisor’s core assets and business mix. We’ll now examine how the revenue...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Should Medpace’s (MEDP) Golden Cross and Upgraded Estimates Prompt a Fresh Look at Its Valuation?

In recent weeks, Medpace Holdings, Inc. experienced a “golden cross,” with its 50-day moving average crossing above the 200-day moving average, alongside upward revisions to earnings estimates. This combination of technical momentum and improving earnings expectations has drawn fresh attention to how the company’s fundamentals align with investors’ views on its future prospects. Next, we will examine how the golden cross and stronger earnings estimates interact with Medpace’s existing...
NasdaqGS:CSCO
NasdaqGS:CSCOCommunications

Cisco Stock And 2 AI Infrastructure Dividend Picks Worth A Closer Look

With the S&P 500 at record highs and valuations flashing similar signals to the late 1990s, many investors worry about where the next painful reset might land. Yet this is also when quality can matter most, as resilient dividend payers may stand out if lofty growth stories disappoint. This article walks through three stocks exposed to today’s AI driven enthusiasm and rich valuations, all drawn from a High-Quality Dividend Growth Stocks screener. The stocks covered below are just a starting...
NasdaqGS:AOSL
NasdaqGS:AOSLSemiconductor

Alpha And Omega Semiconductor (AOSL) Heads Into Earnings With Valuation Still In Focus

Alpha and Omega Semiconductor (AOSL) heads into its upcoming fiscal Q4 2026 report with expectations for a shift from a small profit to a loss and lower year-over-year revenue. See our latest analysis for Alpha and Omega Semiconductor. Against that earnings backdrop, Alpha and Omega Semiconductor’s recent trading has been volatile, with a 1-day share price return of 8.25% and 7-day share price return of 13.67% contrasting with a 30-day share price return that declined 3.94%. Over longer...
NYSE:WEX
NYSE:WEXDiversified Financial

How WEX’s New AI Fraud Controls and Analytics Push Will Impact WEX (WEX) Investors

WEX has rolled out SecureFuel for its North American fleet customers, using detailed transaction data, real-time vehicle information, and AI-powered models to block potentially unauthorized fuel purchases before approval, while also previewing its AI-based Actionable Insights tool for turning fleet and payment data into operational recommendations. This push into AI-driven fraud prevention and analytics deepens WEX’s integration of payments, telematics, and data intelligence, potentially...
NYSE:ASH
NYSE:ASHChemicals

Is Ashland (ASH) Using Its New Advisory Committee to Quietly Redefine Capital Allocation Priorities?

Ashland Inc. previously declared a quarterly cash dividend of US$0.42 per share, payable on September 15, 2026, to shareholders of record on September 1, 2026, alongside reporting third-quarter fiscal 2026 sales of US$497 million and net income of US$16 million. The company also reached a cooperation agreement with Ancora Holdings Group, adding two independent directors and forming a Capital Allocation Advisory Committee, potentially reshaping how Ashland thinks about investment priorities...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) Stock Could Be 28% Undervalued As Guidance Rises

Eli Lilly stock has climbed very sharply over the past five years, yet the current valuation checks send a more measured signal, with the Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market based multiples sit closer to fair value. That mix leaves investors weighing a strong price run against an intrinsic value estimate that suggests the shares may still trade below what the underlying cash flows imply. Eli Lilly has returned about 3.7x over the past 5 years, which...
NYSE:HLF
NYSE:HLFPersonal Products

Is Herbalife (HLF) Undervalued Following Raised Sales Guidance And A Quarterly Loss?

Herbalife (HLF) is back in focus after its second quarter 2026 update, which combined higher sales, a swing to a quarterly net loss, raised full year sales guidance, and confirmation of an upcoming CFO transition. See our latest analysis for Herbalife. The earnings release and CFO succession plan have come alongside a more mixed share price path for Herbalife. The stock has a 1 day share price return of 7.3%, although the 30 day share price return is down 6.1%. Momentum has faded compared to...
NYSE:PRI
NYSE:PRIInsurance

How Investors Are Reacting To Primerica (PRI) Earnings Beat And Expanded Capital Return Program

In the past week, Primerica, Inc. reported second-quarter 2026 results showing revenue of US$865.07 million and net income of US$202.28 million, with both basic and diluted earnings per share from continuing operations rising versus a year earlier. Alongside these earnings, Primerica affirmed a US$1.20 per-share dividend and completed US$270.01 million of share repurchases under its existing buyback, highlighting ongoing capital returns to shareholders. With the latest quarter’s higher...
NasdaqGS:PTC
NasdaqGS:PTCSoftware

PTC (PTC) Deepens AI Across Lifecycle Tools, But How Durable Is Its System‑of‑Record Edge?

In early August 2026, PTC released new versions of its Codebeamer ALM, Codebeamer AI, Pure Variants, and Arena PLM/QMS platforms, adding AI-driven search, automated variant and workflow management, and deeper integrations to help manufacturers keep product changes consistent, compliant, and connected across the product lifecycle. These product enhancements arrived alongside PTC’s updated fiscal 2026 guidance and recent earnings, where the company reported higher year-to-date revenue and...
NYSE:AB
NYSE:ABCapital Markets

AllianceBernstein (AB) Stock Looks Fairly Valued After A 57% Run

AllianceBernstein Holding has delivered a strong 57.1% return over the past three years, yet today the Excess Returns intrinsic value estimate points to a roughly fair price while earnings-based multiples lean toward the stock looking a bit expensive. The 57.1% gain over three years suggests investors have already priced in a lot of good news for AllianceBernstein Holding, which can limit room for further upside without stronger fundamentals. Recent involvement in areas like carbon...
NasdaqGS:CMPS
NasdaqGS:CMPSBiotechs

COMPASS Pathways (CMPS) Joins VA PIVOT Trial, Is The Stock Still Cheap?

The latest move from COMPASS Pathways (NasdaqGS:CMPS) is its new partnership with the U.S. Department of Veterans Affairs on the PIVOT trial, a multi site study of COMP360 in veterans. See our latest analysis for COMPASS Pathways. At a share price of US$13.54, COMPASS Pathways has a 7 day share price return of 19.3% and a 90 day share price return of 40.31%. The 1 year total shareholder return of 208.43% signals strong momentum despite a wider recent loss and a new shelf registration filing...